TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
Use the tabs below to navigate through our Scientific Symposium, Patient Conference, and Patient/Advocate Videos.
Welcome - Jenni Kovach
EHE Biology & What We Know - Brian Rubin, MD, PhD
Towards a Zebrafish Model of EHE - Freek van Eeden, PhD
CRISPR cas9 Models of WWTR1-CAMTA1 Fusion - Fabio Vanoli, PhD
An in vitro model to study the consequences of TAZ-CAMTA1 expression in primary endothelial cells - Valerie Kouskoff, PhD
Genomics and Preclinical Models of Rare Cancers - Holly Barker, PhD
Systematic Screening of ex vivo Conditions for EHE Model Generation - Mushriq Al-Jazrawe, PhD
Development of a cell-based transplantable model of Epithelioid Hemangioendothelioma - Caleb Seavey, MD
Patient-Derived Models of EHE - Nadia Zaffaroni, PhD
Evaluating small molecule protein-protein interaction inhibitors for targeting EHE - Ajaybabu Pobbati, PhD
Inhibiting the tumorigenic function of TAZ-CAMTA1 oncogene - Ryan Kanai
TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex - Keith Garcia
Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis - Frank Szulzewsky, PhD
Modulation of YAP/TAZ in EHE - Aparna Subramaniam, MBBS, MPH
Phase I Clinical Trial Spotlight - TEAD Inhibitor Candidate, IK-930 - Jeff Ecsedy, PhD
Bill Tap, MD, Brian Rubin, MD, PhD, Silvia Stacchiotti, MD, Breelyn Wilky, MD, Paul Huang, PhD & David Casimir, PhD
Co-Chair Close - Bill Tap, MD
Thank You - Jenni Kovach
Welcome - Jenni Kovach
Introduction to ESMO Consensus Paper - Hugh Leonard
Overview of Consensus Paper - Silvia Stacchiotti, MD
EU Medical Oncology Perspective - Professor Robin Jones, MD
Strategies for inhibiting the tumorigenic function of the TAZ-CAMTA1 oncogene - John Lamar, PhD
Epithelioid Hemangioendothelioma: A Brief Overview - Munir Tanas, MD
MSK IMPACT and Secondary Mutations in EHE - Cristina Antonescu, MD
EHE Biobanking in the United States - Brian Rubin, MD, PhD
EHE Biobanking in the United Kingdom - Professor Robin Jones, MD
Consenting Participants - Patty Cogswell
AYA & Adult Program Harmonization at Memorial Sloan Kettering - Katherine Thornton, MD
Coordinating Care - Community Oncology & Academic Medical Centers - Scott Okuno, MD
Intravenous Ketorolac Infusion for Intractable Pleuritic Pain - Case Review - Tamara Vesel, MD / Emma Ernst
Liver Transplant - A Patient Perspective - Andy Donnelly
Navigating Insurance Coverage - A Challenge in Pursuing IRE for Hepatic EHE - Smriti Rai, MD
Irreversible Electroporation for the Treatment of HEHE - Helen Kouvnadias, PhD
Scott Okuno, MD, Tamara Vesel, MD, Breelyn Wilky, MD, Guy Weinberg, MD, & David Casimir, PhD
Closing - Jenni Kovach
Watch as Kim Young shares the challenges of living with the uncertainty of EHE.
Diagnosed with EHE 24 years ago, Dawn Scott has a unique historical perspective and delivers a powerful message of hope and gratitude to the EHE community.
EHE Foundation Board Member Emeritus, Jane Gutkovich provides a timeline of early connections among the EHE community and later formation of The EHE Foundation, all from the perspective of being the mother of an EHE patient.
Denise Robinson, EHE Foundation Board Member and Director of Research, provides an overview of patient-led research initiatives.
EHE Foundation Board Member, Amy Baghdadi details her own journey with EHE as well as milestones of The EHE Foundation.
EHE 360 is organized by The EHE Foundation as part of a patient-led research network, in collaboration with the UK EHE Rare Cancer Charity, the EHE Rare Cancer Foundation Australia, key global patient advocacy groups, and our medical and industry partners. Thank you to our generous donors, volunteers and the support of the CZI Rare As One Project and the Margie & Robert E. Petersen Foundation.
Sign Up for latest updates on EHE 360!